Skip to main content

Advertisement

SpringerLink
Log in

The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Psoriasis is a disease presenting cutaneous, immunological and vascular abnormalities. Oral cyclosporin therapy has been shown to be effective for the disease. Clinical and laboratory findings affecting the response of oral cyclosporin therapy in patients with psoriasis were studied. Forty-seven patients with psoriasis (male:female = 27:20, age 56.7 + 12.6 years) were studied. The response to oral cyclosporin therapy was categorized as excellent, good, fair and poor according to decrease of PASI score and decrease of cyclosporin dose. Clinical and laboratory findings including cyclosporin trough level and high sensitivity-CRP were statistically analyzed. Nine patients showed excellent response, 17 good response, 19 fair response and 2 poor response. High sensitivity-CRP (0.11 ± 0.02 mg/dl) in fair response patients to oral cyclosporin therapy was significantly lower than those in excellent response patients (0.42 ± 0.21 mg/dl) (P ≤ 0.05). Body mass index (23.4 ± 0.6 kg/m2), HDL-cholesterol (57.1 ± 3.6 mg/dl) and fasting plasma glucose (105 ± 5 mg/dl) in fair response patients to oral cyclosporin therapy was significantly lower, higher and lower than those in excellent response patients (25.7 ± 0.9 kg/m2; 43.0 ± 2.8, 140 ± 20 mg/dl) (P < 0.05, P < 0.05, P < 0.05), respectively. No other clinical and laboratory findings showed statistical significance among excellent, good and fair response patients. These results showed the correlation between response of oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barrera P, Boerbooms AM, van de Putte LB, van der Meer JW (1996) Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 25:234–253. doi:10.1016/S0049-0172(96)80035-7

    Article  PubMed  CAS  Google Scholar 

  2. Beresini MH, Davalian D, Alexander S et al (1993) Evaluation of EMIT cyclosporine assay for use with whole blood. Clin Chem 39:2235–2241

    PubMed  CAS  Google Scholar 

  3. Bonora E (2006) The metabolic syndrome and cardiovascular disease. Ann Med 38:64–80. doi:10.1080/07853890500401234

    Article  PubMed  CAS  Google Scholar 

  4. de Beer FC, Hind CR, Fox KM et al (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J 47:239–243. doi:10.1136/hrt.47.3.239

    Article  PubMed  Google Scholar 

  5. Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157:238–244

    Article  PubMed  CAS  Google Scholar 

  6. Gelfand JM, Neimann AL, Shin DB et al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741. doi:10.1001/jama.296.14.1735

    Article  PubMed  CAS  Google Scholar 

  7. Gisondi P, Giglio MD, Cotena C, Girolomoni G (2008) Combining etenercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 158:1345–1349. doi:10.1111/j.1365-2133.2008.08564.x

    Article  PubMed  CAS  Google Scholar 

  8. Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157:68–73. doi:10.1111/j.1365-2133.2007.07986.x

    Article  PubMed  CAS  Google Scholar 

  9. Griffiths CE, Dubertret L, Ellis CN et al (2004) Cyclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 150(Suppl 67):11–23. doi:10.1111/j.0366-077X.2004.05949.x

    Article  PubMed  CAS  Google Scholar 

  10. Griffiths CE, Katsambas A, Dijkmans BA et al (2006) Update on the use of cyclosporin in immune-mediated dermatoses. Br J Dermatol 155(Suppl 2):1–16. doi:10.1111/j.1365-2133.2006.07343.x

    Article  PubMed  CAS  Google Scholar 

  11. Henseler T, Christopher E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32:982–986. doi:10.1016/0190-9622(95)91336-X

    Article  PubMed  CAS  Google Scholar 

  12. Heydendael VM, Spuls PI, Ten Berge IJ et al (2002) Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br J Dermatol 147:122–129. doi:10.1046/j.1365-2133.2002.04836.x

    Article  PubMed  CAS  Google Scholar 

  13. Krueger G, Ellis CN (2005) Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53(Suppl):S94–S100. doi:10.1016/j.jaad.2005.04.035

    Article  PubMed  Google Scholar 

  14. Lebwohl M, Ellis C, Gottlieb A et al (1998) Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 39:464–475. doi:10.1016/S0190-9622(98)70325-1

    Article  PubMed  CAS  Google Scholar 

  15. Libby P (1995) Molecular bases of the acute coronary syndromes. Circulation 91:2844–28450

    PubMed  CAS  Google Scholar 

  16. Liuzzo G, Biasucci LM, Gallimore JR et al (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331:417–424. doi:10.1056/NEJM199408183310701

    Article  PubMed  CAS  Google Scholar 

  17. Losa García JE, Mateos Rodríguez F et al (1998) Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Respir Med 92:722–728. doi:10.1016/S0954-6111(98)90002-6

    Article  PubMed  Google Scholar 

  18. Ludwig RJ, Herzog C, Rostock A et al (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–276. doi:10.1111/j.1365-2133.2006.07562.x

    Article  PubMed  CAS  Google Scholar 

  19. Malerba M, Gisondi P, Radaeli A et al (2006) Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 155:1165–1169. doi:10.1111/j.1365-2133.2006.07503.x

    Article  PubMed  CAS  Google Scholar 

  20. Mallbris L, Akre O, Granath F et al (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19:225–230. doi:10.1023/B:EJEP.0000020447.59150.f9

    Article  PubMed  Google Scholar 

  21. Mallbris L, Ritchlin CT, Stahle M (2006) Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 8:355–363. doi:10.1007/s11926-006-0065-8

    Article  PubMed  CAS  Google Scholar 

  22. Maseri A (1997) Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. N Engl J Med 335:1014–1016. doi:10.1056/NEJM199704033361409

    Article  Google Scholar 

  23. Meyers MR, Gokce N (2007) Endothelial dysfunction in obesity: etiological role in atherosclerosis. Curr Opin Endocrinol Diabetes Obes 14:365–369

    PubMed  CAS  Google Scholar 

  24. Mitamura M, Nakano N, Yonekawa T et al (2007) T cells are involved in the development of arthritis induced by anti-type II collagen antibody. Int Immunopharmacol 7:1360–1368. doi:10.1016/j.intimp.2007.05.021

    Article  PubMed  CAS  Google Scholar 

  25. Mockli G, Kabra PM, Kurtz TW (1990) Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist. J Am Acad Dermatol 23:1275–1279

    Article  PubMed  CAS  Google Scholar 

  26. Neimann AL, Shin DB, Wang X et al (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835. doi:10.1016/j.jaad.2006.08.040

    Article  PubMed  Google Scholar 

  27. Peserico A, Zanetti G, Padovan S et al (1988) Relationship between body weight and blood pressure and some metabolic parameters in psoriatic patients. Br J Dermatol 118:191–194. doi:10.1111/j.1365-2133.1988.tb01773.x

    Article  PubMed  CAS  Google Scholar 

  28. Ridker PM (2001) High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813–1818

    PubMed  CAS  Google Scholar 

  29. Rocha-Pereira P, Santos-Silva A, Rebelo RI et al (2004) The inflammatory response in mild and in severe psoriasis. Br J Dermatol 150:917–928. doi:10.1111/j.1365-2133.2004.05984.x

    Article  PubMed  CAS  Google Scholar 

  30. Schieffer B, Schieffer E, Hilfiker-Kleiner D et al (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372–1378

    PubMed  CAS  Google Scholar 

  31. Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 353:848–850. doi:10.1056/NEJMc051541

    Article  Google Scholar 

  32. Seckin D, Tokgozoglu L, Akkaya S (1994) Are lipoprotein profile and lipoprotein (a) levels altered in men with psoriasis? J Am Acad Dermatol 31:445–449

    Article  PubMed  CAS  Google Scholar 

  33. Seishima M, Seishima M, Mori S, Noma A (1994) Serum lipid and apolipoprotein in patients with psoriasis. Br J Dermatol 130:738–742. doi:10.1111/j.1365-2133.1994.tb03411.x

    Article  PubMed  CAS  Google Scholar 

  34. Shibata N, Hayakawa T, Hoshino N et al (1998) Effect of obesity on cyclosporine trough concentrations in psoriasis patients. Am J Health Syst Pharm 55:1598–1602

    PubMed  CAS  Google Scholar 

  35. Steimer W (1999) Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem 45:371–381

    PubMed  CAS  Google Scholar 

  36. Wakkee M, Thio HB, Presn EP et al (2007) Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Athrosclerosis 190:1–9. doi:10.1016/j.atherosclerosis.2006.07.011

    Article  CAS  Google Scholar 

  37. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346. doi:10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U

    Article  PubMed  CAS  Google Scholar 

  38. Zhu J, Quyyumi AA, Norman JE et al (2000) Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 85:140–146. doi:10.1016/S0002-9149(99)00653-0

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Dokkyo Medical University Koshigaya Hospital, 2-1-50 Mimami-Koshigaya, Koshigaya, Saitama, 343-8555, Japan

    Tsutomu Ohtsuka

Authors
  1. Tsutomu Ohtsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsutomu Ohtsuka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohtsuka, T. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch Dermatol Res 300, 545–550 (2008). https://doi.org/10.1007/s00403-008-0887-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-008-0887-5

Keywords

Search

Navigation